Skip to Content

Vanderbilt-Ingram Cancer CenterVanderbilt-Ingram Cancer Center

Jin  Chen

Jin Chen, M.D., Ph.D.

Professor of Medicine (Rheumatology and Immunology)
Professor of Cell and Development Biology
Professor of Cancer Biology
VICC Member

Contact Information:

Vanderbilt University Medical Center
T-3219 Medical Center North
Nashville, TN 37232-2681

Research Specialty

To investigate the role of Eph receptor tyrosine kinases and their ligands (ephrins) in tumor angiogenesis, tumor metabolism, and cancer stem cells, and to develop inhibitors targeting EphA2 receptor in cancer.

Research Description

Our major focus has been to characterize the role of Eph receptor tyrosine kinases and their ligands, ephrins, in tumor metabolism, cancer metastasis, and tumor angiogenesis. Our approach involves a combination of oncogenomics and proteomics, confocal microscopy and imaging, transgenic and knock out animal models, and traditional cell biology and biochemistry techniques.

Eph RTKs and their ligands are dysregulated in tumor tissues and expression of these molecules is associated with clinical outcome of various cancer types. In particular, EphA2 receptor plays critical roles in both tumor cells and tumor blood vessels. Our laboratory demonstrated that epithelial EphA2 is required for cell proliferation and tumor initiation. We also showed that vascular endothelial EphA2 promotes tumor progression through angiogenesis. As EphA2 regulates both tumor cells and host microenvironment, it is a good target for cancer therapy. Several anti-EphA2 agents have been developed and we are testing selective small molecule Eph receptor kinase inhibitors. Current projects in the lab include:

1. Role of ephrin-A1, the ligand for EphA2 RTK, in tumor metabolism in breast cancer.

2. EphA2 in K-Ras and TKI-resistant EGFR mutant lung cancer and cancer stem cells.

3. Dissecting opposing roles of EphA2 and EphA3 in lung cancer.

4. Regulation of angiocrine signaling in tumor progression, metastasis, and stem cell function.